Epilive 750 Tablet contains Levetiracetam 750 mg, an antiepileptic medication primarily indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and preventing seizure propagation. Epilive 750 is typically prescribed as adjunctive therapy in adults and pediatric patients aged four years and above. The tablet should be administered orally, with or without food, as per the prescribed dosing regimen tailored to the patient’s clinical condition and response. Dose adjustments may be necessary in patients with renal impairment. Common adverse effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or agitation; however, serious adverse events are rare. Caution is advised when initiating therapy in patients with a history of psychiatric disorders. Epilive 750 does not induce hepatic enzymes and has minimal drug-drug interactions, making it suitable for combination therapy. Regular monitoring of clinical response and tolerability is recommended to optimize therapeutic outcomes. Patients should be counseled on adherence and the importance of not discontinuing therapy abruptly to avoid seizure exacerbation.